Overview

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to see if low intensity chemotherapy given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells from a donor can increase the length of remission in patients with leukemia and lymphoma. The safety of this treatment will also be studied.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Biogen
Treatments:
Antibodies, Monoclonal
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Rituximab
Vidarabine